Research programme: cancer immunotherapies - Genocea Biosciences

Drug Profile

Research programme: cancer immunotherapies - Genocea Biosciences

Alternative Names: GEN 010; Neoantigen cancer vaccine - Genocea Biosciences

Latest Information Update: 17 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genocea Biosciences; Memorial Sloan-Kettering Cancer Center
  • Developer Dana-Farber Cancer Institute; Genocea Biosciences; Harvard Medical School; Memorial Sloan-Kettering Cancer Center; US Oncology Research
  • Class Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Malignant melanoma

Most Recent Events

  • 19 Jul 2018 Genocea Biosciences plans a phase I/IIa trial of GEN-009 in Cancer (Monotherapy, Second-line therapy or greater) in the second half of 2018 (Genocea Biosciences pipeline, July 2018)
  • 14 Mar 2018 Genocea plans to file an IND application with the US FDA for GEN 010 in late 2018 (Genocea Biosciences pipeline, March 2018)
  • 01 Jan 2018 Genocea receives patent allowance for ATLAS platform in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top